{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:46:24Z","timestamp":1767991584489,"version":"3.49.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ucl.2019.09.010","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:41:24Z","timestamp":1574167284000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination Intravesical Therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Nathan A.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2019.09.010_bib1","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.010_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.010_bib3","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.010_bib4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.010_bib5","first-page":"1124","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.010_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.010_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.euo.2018.07.006","article-title":"Systematic review of factors associated with the utilization of radical cystectomy for bladder cancer","volume":"2","author":"Williams","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urolonc.2011.08.011","article-title":"Disparities in bladder cancer","volume":"30","author":"Jacobs","year":"2012","journal-title":"Urol Oncol Semin Original Invest"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.010_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4161\/cbt.6.6.4088","article-title":"Interferon-\u03b1 induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells","volume":"6","author":"Papageorgiou","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.010_bib10","first-page":"2489","article-title":"Biological properties of recombinant \u03b1-interferons: 40th anniversary of the discovery of interferons","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.010_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-4295(97)00303-8","article-title":"Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Gu\u00e9rin and interferon-alpha","volume":"50","author":"Jimenez-Cruz","year":"1997","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.010_bib12","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-\u03b1 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.010_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol Semin Original Invest"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.010_bib14","first-page":"888","article-title":"Interim results from a national,multicenter phase II trial of combination BCG plus IFN alpha 2B for superficial bladder cancer","volume":"172","author":"O\u2019Donnell Michael","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.010_bib15","first-page":"1634","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.010_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Gu\u00e9rin failure pattern on subsequent response to bacille Calmette-Gu\u00e9rin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.010_bib17","first-page":"817","article-title":"Factors affecting response to bacillus Calmette-Gu\u00e9rin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/BLC-180203","article-title":"Multi-perspective tolerance evaluation of bacillus Calmette-Guerin with interferon in the treatment of non-muscle invasive bladder cancer","volume":"5","author":"Steinberg","year":"2019","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.010_bib19","first-page":"1915","article-title":"Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.010_bib20","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin with interferon-alpha versus intravesical bacillus Calmette-Gu\u00e9rin for treating non-muscle-invasive bladder cancer","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cei.12875","article-title":"Considerations for successful cancer immunotherapy in aged hosts","volume":"187","author":"Hurez","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.ucl.2019.09.010_bib22","doi-asserted-by":"crossref","first-page":"e113951","DOI":"10.1371\/journal.pone.0113951","article-title":"Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice","volume":"9","author":"Nandakumar","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-\u03b3 production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.010_bib24","first-page":"670.e7-14","article-title":"Quadruple immunotherapy of bacillus Calmette-Gu\u00e9rin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol Semin Original Invest"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.010_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2017.06.012","article-title":"Systematic review of immune checkpoint inhibition in urological cancers","volume":"72","author":"Rijnders","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.010_bib26","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette\u2013Gu\u00e9rin and anti-PD-l1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco targets Ther"},{"issue":"8","key":"10.1016\/j.ucl.2019.09.010_bib27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.010_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2019.09.010_bib29","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1245\/s10434-018-6610-7","article-title":"Cancer immune therapy: prognostic significance and implications for therapy of PD-1 in BCG-relapsing bladder cancer","volume":"25","author":"Mukherjee","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.010_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/2326-6066.CIR-15-0176","article-title":"Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor","volume":"4","author":"Vandeveer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"Supplement 4","key":"10.1016\/j.ucl.2019.09.010_bib31","first-page":"e616","article-title":"MP43-01; phase 2 keynote-057 study: pembrolizumab for patients with high-risk non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin","volume":"201","author":"Kulkarini","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"Supplement 4","key":"10.1016\/j.ucl.2019.09.010_bib32","first-page":"e620","article-title":"MP43-09; phase I trial of intravesical bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in high grade nonmuscle invasive bladder cancer","volume":"201","author":"Alanee","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2019.09.010_bib33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenetics Genomics"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","article-title":"Mitomycin C: mechanism of action, usefulness and limitations","volume":"1","author":"Verweij","year":"1990","journal-title":"Anticancer Drugs"},{"issue":"3 Part 1","key":"10.1016\/j.ucl.2019.09.010_bib35","first-page":"531","article-title":"Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder","volume":"141","author":"Fukui","year":"1989","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib36","first-page":"27","article-title":"Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result","volume":"151","author":"Sekine","year":"1994","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.010_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.urolonc.2010.06.012","article-title":"A\u00a0cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer","volume":"30","author":"Chen","year":"2012","journal-title":"Urol Oncol Semin Original Invest"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-a2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.010_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2016.03.034","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus combination of epirubicin and interferon-\u03b12a in reducing recurrence of non\u2013muscle-invasive bladder carcinoma: FinnBladder-6 study","volume":"70","author":"Marttila","year":"2016","journal-title":"Eur Urol"},{"issue":"4S","key":"10.1016\/j.ucl.2019.09.010_bib40","first-page":"e175","article-title":"MP15-13 a phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory non-muscle invasive urothelial carcinoma of the bladder","volume":"197","author":"DeCastro","year":"2017","journal-title":"J\u00a0Urol"},{"issue":"Supplement 4","key":"10.1016\/j.ucl.2019.09.010_bib41","first-page":"e623","article-title":"MP43-14;a phase 1 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder","volume":"201","author":"DeCastro","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"4S","key":"10.1016\/j.ucl.2019.09.010_bib42","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Seminars in oncology"},{"issue":"4S","key":"10.1016\/j.ucl.2019.09.010_bib43","first-page":"271","article-title":"840: Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer","volume":"175","author":"Maymi Jose","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.010_bib44","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non\u2013muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.010_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0305-7372(03)00097-5","article-title":"Mode of action of docetaxel\u2013a basis for combination with novel anticancer agents","volume":"29","author":"Herbst","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.010_bib47","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bju.14423","article-title":"Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes","volume":"122","author":"Pandey","year":"2018","journal-title":"BJU Int"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2019.09.010_bib48","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2017.35.15_suppl.4546","article-title":"Oncological outcomes of intravesical gemcitabine and docetaxel for select patients with high grade recurrent NMIBC","volume":"35","author":"Milbar","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.010_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.010_bib50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"issue":"4, Supplement","key":"10.1016\/j.ucl.2019.09.010_bib51","first-page":"e1167","article-title":"LBA27 phase 3 study of vicinium in BCG-unresponsive non-muscle invasive bladder cancer: initial results","volume":"199","author":"Dickstein","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2019.09.010_bib52","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2018.36.6_suppl.510","article-title":"Phase Ib trial of ALT-803, an IL-15 superagonist, plus BCG for the treatment of BCG-na\u00efve patients with non-muscle-invasive bladder cancer","volume":"36","author":"Rosser","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.010_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/cancers9020015","article-title":"Systemic immunotherapy for urothelial cancer: current trends and future directions","volume":"9","author":"Gupta","year":"2017","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2019.09.010_bib54","doi-asserted-by":"crossref","first-page":"TPS4590","DOI":"10.1200\/jco.2014.32.15_suppl.tps4590","article-title":"A\u00a0randomized, prospective, phase II study to determine the efficacy of BCG given in combination with PANVAC versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG","volume":"32","author":"Brancato","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.010_bib55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11934-018-0852-6","article-title":"Current clinical trials in non-muscle invasive bladder cancer","volume":"19","author":"Nykopp","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2019.09.010_bib56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2017.35.6_suppl.313","article-title":"A\u00a0phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder","volume":"35","author":"DeCastro","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.010_bib57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/0970-1591.166475","article-title":"Treatment options in non-muscle-invasive bladder cancer after BCG failure","volume":"31","author":"Brooks","year":"2015","journal-title":"Indian J Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:38:15Z","timestamp":1758807495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014319300886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0094014319300886"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.010","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Intravesical Therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}